3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Head & Neck
1
Conditions
Breast Neoplasms
8
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
44
Paclitaxel
37
Carboplatin
30
Doxorubicin
11
Cisplatin
11
Bevacizumab
11
lenvatinib
9
Nivolumab
9
Docetaxel
9
Fulvestrant
8
Gemcitabine
7
Oxaliplatin
6
Fluorouracil
6
Pemetrexed
5
Letrozole
5
Ipilimumab
5
Cetuximab
5
spartalizumab
4
selinexor
4
dostarlimab
4
Trastuzumab
4
Irinotecan
4
trastuzumab deruxtecan
3
tisotumab vedotin
3
serabelisib
3
sacituzumab govitecan
3
ribociclib
3
olaparib
3
epacadostat
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endometrial Neoplasms
×
Imlunestrant
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled